NCT04282187View on ClinicalTrials.gov

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 24, 2020

Primary Completion Date

November 11, 2026

Study Completion Date

November 11, 2026

Conditions
Acute Myeloid LeukemiaEssential ThrombocythemiaMyelodysplastic SyndromeMyelodysplastic/Myeloproliferative NeoplasmMyeloproliferative NeoplasmMyeloproliferative Neoplasm, Not Otherwise SpecifiedPolycythemia VeraPrimary MyelofibrosisSecondary Myelofibrosis
Interventions
DRUG

Decitabine

Given IV

DRUG

Ruxolitinib

Given PO

DRUG

Fedratinib

Given PO

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Pacritinib

Given PO

PROCEDURE

Biospecimen Collection

Undergo collection of blood and bone marrow samples

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
lead

University of Washington

OTHER